Piracetam, 200 mg/ml 5 ml 10 pcs

The active ingredient is piracetam, a cyclic derivative of gamma-aminobutyric acid (GABA).

Piracetam is a nootropic which directly affects the brain, improving cognitive (learning) processes such as learning, memory, attention, and mental performance.

Piracetam affects the CNS in different ways: by changing the speed of propagation of excitation in the brain, improves metabolic processes in nerve cells, improves microcirculation, affects the rheological characteristics of the blood, without having a vasodilatory effect. It improves communication between the cerebral hemispheres and synaptic conduction in the neocortical structures, improves cerebral blood flow.

Piracetam inhibits platelet aggregation and restores the configuration properties of the outer membrane of rigid red blood cells, as well as the ability of the latter to pass through the vessels of the microcircular bed. At a dose of 9.6 g it reduces the concentration of fibrinogen and Willebrand factors by 30-40 % and prolongs the bleeding time. Piracetam has a protective and restorative effect in cases of brain dysfunction due to hypoxia and intoxication.

Piracetam reduces the severity and duration of vestibular nystagmus.

Indications

In adults:
– Symptomatic treatment of psychoorganic syndrome accompanied by decreased memory, decreased concentration and activity, mood changes, behavioral disorders, gait disturbances;
– Treatment of vertigo and related balance disorders (except for vertigo of vasomotor and psychogenic origin);
– Treatment of cortical myoclonias (monotherapy or as a part of complex therapy);
– Control of sickle-cell vasocclusive crisis.
In children:
– treatment of dyslexia in children from 8 years old in combination with other methods;
– curing sickle cell vasoocclusive crisis.

Active ingredient

Composition

1 ampoule of piracetam 1 g

How to take, the dosage

Injection or drip, i.m. The daily dose is divided into 2-4 doses.

Symptomatic treatment of psychoorganic syndrome: 4.8 g/day for the first week, then a maintenance dose of 1.2-2.4 g/day is given.

The treatment of dizziness and related balance disorders: 2.4-4.8 g/day.

The treatment of cortical myoclonias: start with a dose of 7.2 g/day, every 3-4 days the dose is increased by 4.8 g/day until a maximum dose of 24 g/day is reached. Treatment is continued throughout the entire period of the disease. Every 6 months it should be tried to reduce a dose or discontinue preparation, gradually reducing a dose by 1.2 g/day every 2 days. If there is little or no therapeutic effect, treatment should be discontinued.

In sickle cell vaso-occlusive crisis (in adults and children): intravenously at 300 mg/kg/day divided into 4 equal doses.

The treatment of dyslexia in children over 8 years of age (in combination with other treatments): 3.2 g divided into 2 equal doses.

In chronic renal failure of mild degree (KK 50-79 ml/min), 2/3 dose divided into 2-3 doses; of moderate degree (KK 30-49 ml/min), 1/3 dose divided into 2 doses; of severe degree (KK 20-30 ml/min), 1/6 dose once.

Interaction

Concomitant use with iodine-containing thyroid hormones may result in confusion, irritability and sleep disturbance.

In high doses (9.6 g/day) in patients with venous thrombosis increases the anticoagulant effect of indirect anticoagulants (more pronounced reduction of platelet aggregation, fibrinogen, Willebrand factor, blood and plasma viscosity).

Pharmaceutically compatible with solutions of dextrose (5%, 10%, 20%), fructose (5%, 10%, 20%), 0.9% sodium chloride solution, Ringer’s solution, 20% mannitol solution, hydroxyethyl starch (6%, 10%).

Special Instructions

Cautiously prescribed in patients with impaired hemostasis, before upcoming major surgical interventions or in patients with symptoms of severe bleeding.

In the treatment of cortical myoclonias, abrupt discontinuation of treatment should be avoided as it may cause recurrence of seizures.
In long-term therapy in elderly patients, regular monitoring of renal function is recommended, with dose adjustments depending on CK if necessary.

It penetrates through the filter membranes of hemodialysis machines.

Impact on driving and operating machinery

At the time of treatment, care must be taken when driving vehicles and engaging in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

Contraindications

– severe chronic renal insufficiency (creatinine clearance (KK) less than 20 ml/min);
– hemorrhagic stroke;
– psychomotor agitation;
– Huntington’s chorea;
– pregnancy;
– lactation.
With caution: haemostasis disorder; major surgical interventions; severe bleeding; chronic renal insufficiency (KK 20-80 ml/min).

Side effects

CNS disorders: motor disinhibition, irritability, somnolence, depression, asthenia, headache, insomnia, mental agitation, impaired balance, ataxia, worsening of epilepsy, anxiety, hallucinations, confusion.

Digestive system disorders: nausea, vomiting, diarrhea, abdominal pain.

Metabolism: weight gain. Sensory system: vertigo.

Skin disorders: dermatitis, itching, rash.

Allergic reactions: hypersensitivity, anaphylactic reactions, angioedema.
Local reactions: pain at the injection site, thrombophlebitis. Other: fever, decreased blood pressure.

Overdose

Symptoms: abdominal pain, diarrhea with blood.

Treatment: induction of vomiting, gastric lavage, symptomatic therapy, hemodialysis (effectiveness 50-60%). There is no specific antidote.

Similarities